vs
Side-by-side financial comparison of KeyCorp (KEY) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.0B, roughly 1.2× KeyCorp). KeyCorp runs the higher net margin — 25.4% vs 25.3%, a 0.2% gap on every dollar of revenue. On growth, KeyCorp posted the faster year-over-year revenue change (131.8% vs 3.0%). KeyCorp produced more free cash flow last quarter ($2.1B vs $732.0M). Over the past eight quarters, KeyCorp's revenue compounded faster (14.4% CAGR vs 4.4%).
Key is a Japanese visual novel studio known for making dramatic and plot-oriented titles. It was formed on July 21, 1998, as a brand under the publisher Visual Arts, and is located in Kita, Osaka.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
KEY vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $2.4B |
| Net Profit | $510.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 32.3% | 31.9% |
| Net Margin | 25.4% | 25.3% |
| Revenue YoY | 131.8% | 3.0% |
| Net Profit YoY | 309.0% | 3.8% |
| EPS (diluted) | $0.43 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.0B | $2.4B | ||
| Q3 25 | $1.9B | $2.4B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | $1.8B | $2.2B | ||
| Q4 24 | $865.0M | $2.3B | ||
| Q3 24 | $695.0M | $2.4B | ||
| Q2 24 | $1.5B | $2.4B | ||
| Q1 24 | $1.5B | $2.2B |
| Q4 25 | $510.0M | $603.0M | ||
| Q3 25 | $489.0M | $721.0M | ||
| Q2 25 | $425.0M | $718.0M | ||
| Q1 25 | $405.0M | $631.0M | ||
| Q4 24 | $-244.0M | $581.0M | ||
| Q3 24 | $-410.0M | $682.0M | ||
| Q2 24 | $274.0M | $624.0M | ||
| Q1 24 | $219.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 32.3% | 31.9% | ||
| Q3 25 | 31.8% | 37.0% | ||
| Q2 25 | 29.3% | 36.7% | ||
| Q1 25 | 29.0% | 36.5% | ||
| Q4 24 | -92.6% | 31.6% | ||
| Q3 24 | -72.8% | 36.6% | ||
| Q2 24 | 22.0% | 33.0% | ||
| Q1 24 | 18.1% | 34.1% |
| Q4 25 | 25.4% | 25.3% | ||
| Q3 25 | 25.8% | 30.0% | ||
| Q2 25 | 23.1% | 29.2% | ||
| Q1 25 | 22.8% | 28.4% | ||
| Q4 24 | -54.7% | 25.1% | ||
| Q3 24 | -59.0% | 28.6% | ||
| Q2 24 | 18.0% | 26.4% | ||
| Q1 24 | 14.3% | 27.4% |
| Q4 25 | $0.43 | $1.37 | ||
| Q3 25 | $0.41 | $1.63 | ||
| Q2 25 | $0.35 | $1.61 | ||
| Q1 25 | $0.33 | $1.41 | ||
| Q4 24 | $-0.30 | $1.29 | ||
| Q3 24 | $-0.47 | $1.50 | ||
| Q2 24 | $0.25 | $1.37 | ||
| Q1 24 | $0.20 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.2B | — |
| Total DebtLower is stronger | $9.9B | — |
| Stockholders' EquityBook value | $20.4B | $3.3B |
| Total Assets | $184.4B | $15.5B |
| Debt / EquityLower = less leverage | 0.49× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.2B | — | ||
| Q3 25 | $13.3B | $2.1B | ||
| Q2 25 | $11.6B | $1.4B | ||
| Q1 25 | $15.3B | $1.7B | ||
| Q4 24 | $17.5B | $2.0B | ||
| Q3 24 | $22.8B | $1.7B | ||
| Q2 24 | $15.5B | $1.6B | ||
| Q1 24 | $13.2B | $2.0B |
| Q4 25 | $9.9B | — | ||
| Q3 25 | $10.9B | — | ||
| Q2 25 | $12.1B | — | ||
| Q1 25 | $12.4B | — | ||
| Q4 24 | $12.1B | — | ||
| Q3 24 | $15.7B | — | ||
| Q2 24 | $16.9B | — | ||
| Q1 24 | $20.8B | — |
| Q4 25 | $20.4B | $3.3B | ||
| Q3 25 | $20.1B | $5.4B | ||
| Q2 25 | $19.5B | $5.0B | ||
| Q1 25 | $19.0B | $4.7B | ||
| Q4 24 | $18.2B | $4.8B | ||
| Q3 24 | $16.9B | $5.2B | ||
| Q2 24 | $14.8B | $5.0B | ||
| Q1 24 | $14.5B | $5.1B |
| Q4 25 | $184.4B | $15.5B | ||
| Q3 25 | $187.4B | $15.2B | ||
| Q2 25 | $185.5B | $14.5B | ||
| Q1 25 | $188.7B | $14.1B | ||
| Q4 24 | $187.2B | $14.2B | ||
| Q3 24 | $189.8B | $14.4B | ||
| Q2 24 | $187.4B | $14.2B | ||
| Q1 24 | $187.5B | $14.3B |
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.65× | — | ||
| Q4 24 | 0.67× | — | ||
| Q3 24 | 0.93× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 1.43× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2B | $893.0M |
| Free Cash FlowOCF − Capex | $2.1B | $732.0M |
| FCF MarginFCF / Revenue | 104.8% | 30.7% |
| Capex IntensityCapex / Revenue | 5.3% | 6.7% |
| Cash ConversionOCF / Net Profit | 4.33× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $3.5B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.2B | $893.0M | ||
| Q3 25 | $396.0M | $938.0M | ||
| Q2 25 | $1.2B | $486.0M | ||
| Q1 25 | $-140.0M | $587.0M | ||
| Q4 24 | $664.0M | $905.0M | ||
| Q3 24 | $-1.2B | $951.0M | ||
| Q2 24 | $-217.0M | $502.0M | ||
| Q1 24 | $359.0M | $595.0M |
| Q4 25 | $2.1B | $732.0M | ||
| Q3 25 | $367.0M | $805.0M | ||
| Q2 25 | $1.2B | $308.0M | ||
| Q1 25 | $-150.0M | $438.0M | ||
| Q4 24 | $599.0M | $689.0M | ||
| Q3 24 | $-1.2B | $784.0M | ||
| Q2 24 | $-230.0M | $370.0M | ||
| Q1 24 | $347.0M | $455.0M |
| Q4 25 | 104.8% | 30.7% | ||
| Q3 25 | 19.4% | 33.5% | ||
| Q2 25 | 65.8% | 12.5% | ||
| Q1 25 | -8.5% | 19.7% | ||
| Q4 24 | 69.2% | 29.7% | ||
| Q3 24 | -175.8% | 32.8% | ||
| Q2 24 | -15.1% | 15.7% | ||
| Q1 24 | 22.6% | 20.8% |
| Q4 25 | 5.3% | 6.7% | ||
| Q3 25 | 1.5% | 5.5% | ||
| Q2 25 | 1.3% | 7.2% | ||
| Q1 25 | 0.6% | 6.7% | ||
| Q4 24 | 7.5% | 9.3% | ||
| Q3 24 | 2.4% | 7.0% | ||
| Q2 24 | 0.9% | 5.6% | ||
| Q1 24 | 0.8% | 6.4% |
| Q4 25 | 4.33× | 1.48× | ||
| Q3 25 | 0.81× | 1.30× | ||
| Q2 25 | 2.90× | 0.68× | ||
| Q1 25 | -0.35× | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | -0.79× | 0.80× | ||
| Q1 24 | 1.64× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KEY
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
